Treatment-induced adaptive immunosuppression in EGFR-mutant lung cancer

Description of the granted funding

In this project, we will investigate how targeted therapy in lung cancer influence the tumor immune response. Cancer cells that change during treatment may affect the tumor immune response. This could have a significant impact on treatment efficacy and the development of resistance. The project utilizes new mouse models and advanced single-cell techniques to comprehensively investigate the targeted therapy -induced changes in the tumor immune response in lung cancer, and to understand in detail the role of treatment-altered cancer cells in regulating the immune response. Our ultimate goal is to develop and test new ways to treat lung cancer.
Show more

Starting year

2025

End year

2029

Granted funding

Kari Kurppa Orcid -palvelun logo
599 271 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Decision maker

Scientific Council for Biosciences, Health and the Environment
16.06.2025

Other information

Funding decision number

370023

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

cancer